Masahiro Ogasawara

5PUBLICATIONS
0CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 15, 2025
Impact of Reduction in Myeloid-derived Suppressor Cells by Wilms' Tumor 1-targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients.

Masahiro Ogasawara, Mamiko Miyashita, Yuka Yamagishi

|Apr 14, 2025
Combined immunotherapy employing Wilms' tumor 1 peptide-pulsed dendritic cells and hormone or chemotherapeutic agents in patients with metastatic castration resistant prostate cancer.

Masahiro Ogasawara, Mamiko Miyashita, Yuka Yamagishi

|Dec 27, 2023
Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.

Masahiro Ogasawara

|Feb 15, 2022
Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma.

Masahiro Ogasawara, Mamiko Miyashita, Yuka Yamagishi

|Dec 17, 2021
Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.

Shuichi Ota, Mamiko Miyashita, Yuka Yamagishi

Pageof 1

Frequent Collaborators